Alvotech (ALVO) Net Income towards Common Stockholders (2021 - 2026)
Alvotech's (ALVO) quarterly Net Income towards Common Stockholders came in at $1.0 million in Q1 2026, down 99.06% YoY from $109.7 million in Q1 2025, and down 99.06% on a QoQ basis from $109.7 million in Q4 2025.
Alvotech (ALVO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Alvotech (ALVO) has 6 years of Net Income towards Common Stockholders data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 99.06% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$306.8 million (down 14.14% YoY) and the FY2025 annual result came in at $109.7 million, up 144.43% from the prior year.
- Net Income towards Common Stockholders slipped to $1.0 million in Q1 2026, from $109.7 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $264.7 million in Q2 2022 to a low of -$651.1 million in Q4 2023.
- A 5-year average of -$99.7 million and a median of -$58.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 362.17% — and 2025, when it jumped 51566.14%.
- Tracing ALVO's Net Income towards Common Stockholders over 5 years: stood at -$540.7 million in 2022, then declined by 20.43% to -$651.1 million in 2023, then surged by 65.69% to -$223.4 million in 2024, then jumped by 149.1% to $109.7 million in 2025, then plunged by 99.06% to $1.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $1.0 million (Q1 2026), $109.7 million (Q4 2025), and -$307.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alvotech | 1.23 Bn | 1.23 Bn | 5.09 Mn | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 109.68 Mn |
| Sep 30, 2025 | -307.87 Mn |
| Jun 30, 2025 | -109.68 Mn |
| Mar 31, 2025 | 109.68 Mn |
| Dec 31, 2024 | -223.39 Mn |
| Sep 30, 2024 | -303.58 Mn |
| Jun 30, 2024 | 148.46 Mn |
| Mar 31, 2024 | -213,111.00 |
| Dec 31, 2023 | -651.14 Mn |
| Aug 31, 2023 | -86.85 Mn |
| Jun 30, 2023 | 138.48 Mn |
| Mar 31, 2023 | -246,152.00 |
| Dec 31, 2022 | -540.69 Mn |
| Aug 31, 2022 | -184.47 Mn |
| Jun 30, 2022 | 264.69 Mn |
| Mar 31, 2022 | -58.90 Mn |
| Dec 31, 2021 | 206.23 Mn |
| Sep 30, 2021 | -33.79 Mn |